Androgen Insensitivity Syndrome is a genetic condition in which the body’s cells do not respond normally to androgens (male-type sex hormones such as testosterone and DHT). Most people with AIS have one X and one Y chromosome (46,XY), and they make typical amounts of androgens, but because the androgen receptor (AR) does not work properly, those hormone signals are not read correctly. This changes sex development before birth and at puberty. Depending on how much the receptor still works, the outer body can look typically female, somewhere in-between, or typically male with fertility problems. NCBI+2MedlinePlus+2 AIS is almost always caused by disease-causing changes (variants) in the AR gene on the X chromosome (Xq11–12), so the receptor cannot bind hormone, enter the nucleus, bind DNA, or turn on target genes normally. MedlinePlus+1
Androgen Insensitivity Syndrome is a genetic condition where a person with XY chromosomes has a change in the androgen receptor (AR) gene, so body tissues do not respond fully (or at all) to androgens such as testosterone and dihydrotestosterone. This can lead to a typical female appearance (complete AIS, CAIS), variable genital development (partial AIS, PAIS), or male appearance with subtle features (mild AIS, MAIS). AIS is X-linked, often inherited from a carrier mother, but many cases are new mutations. Health care focuses on identity-respectful, shared decision-making, pubertal care, bone health, sexual function, and cancer-risk counseling for internal testes. MedlinePlus+3NCBI+3MedlinePlus+3
Other names
Androgen resistance syndrome (describes the same idea: body resists androgens).
46,XY DSD due to androgen receptor defect (modern clinical wording).
Morris syndrome (often used for complete AIS).
Testicular feminization syndrome (older term; now discouraged). Genetic Rare Diseases Info Center+2The Lancet+2
Types
In everyday language, AIS spans a spectrum based on how much androgen signaling remains:
Complete AIS (CAIS): Body cannot “hear” androgens at all. External genitalia look typically female; puberty brings breast development (from aromatized estrogen) but no menstrual periods and little or no pubic/underarm hair; internal uterus is absent; testes are present but undescended. The Lancet+1
Partial AIS (PAIS): Body “hears” androgens a little. Genital appearance varies widely, from mostly female to mostly male with hypospadias or small penis; undescended testes are common; puberty changes vary and gynecomastia (breast growth) may occur. Genetic Rare Diseases Info Center+1
Mild AIS (MAIS): Body “hears” androgens mostly, but not fully. Genitalia look typically male; common issues are reduced facial/body hair, gynecomastia, and infertility. NCBI
Clinicians sometimes grade the outward appearance using the Quigley scale (from “fully masculinized” to “fully feminized”) to describe the spectrum; it’s only a description tool and not a cause. Endocrine Society
Causes
Important: In AIS, “causes” are different ways the AR gene or receptor can be altered. Each mechanism below can independently lead to the clinical picture of AIS.
Missense change in the ligand-binding domain (LBD): A single amino-acid swap weakens binding to testosterone/DHT, so the signal never starts. ScienceDirect
Missense change in the DNA-binding domain (DBD): Receptor reaches DNA poorly, so target genes are not switched on. ScienceDirect
Missense change in the N-terminal transactivation domain (AF-1): Receptor binds hormone but cannot recruit the transcription machinery efficiently. ScienceDirect
Hinge-region variants: Disrupt nuclear entry or mobility of the receptor after binding hormone. ScienceDirect
Nonsense variants: Early stop signs truncate the receptor so it cannot function. Nature
Frameshift variants: Insertion/deletion shifts the reading frame; the protein becomes nonfunctional. European Review
Canonical splice-site variants: Exons are skipped or mis-spliced; key domains are lost. European Review
Large deletions/duplications in AR: Remove or duplicate one or more exons; the receptor is absent or malformed. saintfrancis.com
Promoter/5’ UTR variants: Reduce AR gene expression so too little receptor is made. ScienceDirect
3’ UTR variants: Disturb mRNA stability/translation, lowering receptor levels. ScienceDirect
Altered co-activator interaction sites (especially AF-2 in LBD): Receptor cannot recruit helper proteins needed to start gene transcription. ScienceDirect
Defective dimerization interface: Receptor cannot pair with itself on DNA; target genes stay off. ScienceDirect
Post-zygotic (somatic) mosaicism in AR: Only some cells carry the variant; the degree of insensitivity depends on the mosaic pattern. NCBI
De novo AR variant: The change arises new in the child (not inherited); inheritance still appears X-linked because the gene is on the X. Wikipedia
X-linked recessive transmission from a carrier mother: The most common family pattern; 46,XY children express the altered AR; 46,XX carriers usually have no symptoms. Genetic Rare Diseases Info Center
Compound effects of “milder” AR variants plus modifiers: Some variants reduce activity slightly; together with other factors they can cause MAIS/PAIS. PMC
AR variants that impair response specifically to DHT more than testosterone: Phenotype leans toward undervirilization despite normal androgen production. ScienceDirect
AR variants that alter nuclear localization signals: Receptor binds hormone but fails to accumulate in the nucleus. ScienceDirect
AR variants that reduce stability/half-life of the protein: The receptor degrades faster, lowering functional levels. ScienceDirect
Rare intronic/regulatory changes revealed by modern sequencing: Non-coding changes can still disrupt AR expression or splicing. NCBI
(Note: conditions like 5-alpha-reductase deficiency or androgen-biosynthesis defects can look similar, but they are not AIS because the AR is intact; doctors test for these during diagnosis to avoid confusion.) NCBI
Symptoms and Signs
Because AIS is a spectrum, not everyone has all findings. Below are common, plain-English descriptions across CAIS, PAIS, and MAIS.
Typical female-appearing external genitalia in a person with XY chromosomes (common in CAIS). The uterus is usually absent and the vagina may be shorter. The Lancet
No periods during the teen years (primary amenorrhea) in someone raised as a girl. MedlinePlus
Little or no pubic and underarm hair despite normal or tall growth and breast development at puberty (CAIS). The Lancet
Inguinal or labial lumps in infancy/childhood (undescended testes; sometimes found during hernia repair). nhs.uk
Breast development at puberty (estrogen made from testosterone by aromatase), even when pubic hair is sparse. The Lancet
Infertility (common across the spectrum; males with MAIS can have low sperm counts). NCBI
Hypospadias (urethral opening not at the tip), small penis, or bifid/scrotal differences (typical in PAIS). Genetic Rare Diseases Info Center
Gynecomastia (breast growth in a person with testes), often in PAIS/MAIS. Genetic Rare Diseases Info Center
Undescended testes (cryptorchidism), with possible discomfort or concern about positioning. PMC
Shorter vaginal canal that can cause insertion discomfort; counseling and non-surgical options are often effective when desired. The Lancet
Normal or taller height with otherwise female secondary sex traits in CAIS. The Lancet
Psychological stress around identity, fertility, or disclosure (addressed by specialized DSD teams to support the person and family). NCBI+1
Gonadal tumor risk over time in undescended testes (varies by phenotype and age; clinicians individualize timing of gonadectomy/surveillance). The Lancet
Sparse body/facial hair even when testosterone levels are normal or high (MAIS/PAIS). NCBI
Atypical genital appearance at birth prompting a specialized evaluation (PAIS). NCBI
Diagnostic Tests
A) Physical examination
Whole-body and puberty staging: Doctors look at height, body proportions, breast stage, and hair pattern to see how puberty is progressing and whether estrogen is acting without typical androgen effects. NCBI
External genital exam (newborn/child): A careful, respectful description of the genital anatomy, often using standard descriptors to document what is seen (no single look “defines” someone’s sex). NCBI
Inguinal/labial/scrotal palpation: Feeling for gonads (testes) in the groin or labia; in CAIS they are often undescended and may present as hernias. nhs.uk
Assessment for uterus/vaginal depth (adolescence): Absence of a uterus and a shorter vaginal canal suggest AIS in someone with female external anatomy and no periods. nhs.uk
Skin/hair evaluation: Sparse pubic/axillary hair with otherwise feminizing puberty is a classic CAIS clue. The Lancet
B) Manual/bedside measures
Stretched penile length (SPL) and anogenital measurements (newborns/children): Simple bedside measurements help document virilization objectively. NCBI
Prader orchidometer (testis volume): A chain of beads used to estimate testicular size during exams. NCBI
External masculinization scoring systems (e.g., EMS): Standardized scores help track phenotype over time and between clinicians. NCBI
Quigley phenotypic grading (descriptive): Grades outward appearance along the AIS spectrum (a description tool—not a diagnosis by itself). Endocrine Society
Pelvic exam with utmost consent and sensitivity (teens/adults who desire exam): Evaluates vaginal length/comfort and helps plan supportive options if desired. Translational Pediatrics
C) Laboratory & pathology tests
Karyotype (chromosome test): Confirms 46,XY in most AIS and rules out other chromosome patterns. nhs.uk
AR gene testing (sequencing ± deletion/duplication): The key test; identifies disease-causing AR variants and clarifies inheritance. MedlinePlus
Baseline hormones (LH, FSH, testosterone, estradiol, SHBG): In AIS, testosterone is normal/high with high LH; estradiol can be normal from aromatization. Pattern helps distinguish AIS from androgen-biosynthesis defects. AEM SBEM+1
hCG stimulation test: Checks the testes’ ability to make testosterone; in AIS production is typically normal, pointing to a receptor problem. NCBI
DHT and T:DHT ratio: Helps rule out 5-alpha-reductase deficiency (an important look-alike condition) when evaluating undervirilization. NCBI
AMH (anti-Müllerian hormone) and inhibin B: Suggest functioning Sertoli cells and presence of testicular tissue. NCBI
Gonadal pathology (if surgery/biopsy is done): Confirms testicular tissue, checks for tumor in undescended testes; not routine unless clinically indicated. The Lancet
Family/carrier testing: Once a pathogenic AR variant is known, relatives can choose testing for reproductive planning. nhs.uk
D) Electrodiagnostic tests
Electrodiagnostic studies are not standard for AIS. AIS affects hormone signaling, not nerves or muscles, so nerve conduction studies or EMG are not part of routine care; they would only be used if unrelated neurologic symptoms existed. NCBI
No routine ECG/EEG need specific to AIS. These may be obtained for other reasons but are not part of AIS diagnosis. NCBI
E) Imaging
Pelvic/inguinal ultrasound: Looks for testicular tissue and usually shows no uterus in CAIS/PAIS; it is non-invasive and commonly used first. nhs.uk
MRI pelvis/inguinal region: Maps gonad location when ultrasound is unclear and assists surgical planning if needed. The Lancet
Testicular ultrasound (later surveillance): Monitors undescended or relocated testes for abnormalities over time, when surveillance is chosen. The Lancet
DXA bone density (adolescence/adulthood): Checks bone health, especially after gonadectomy and during/after estrogen therapy. NCBI
Diagnostic laparoscopy (procedure, not imaging, but used for localization/management): Occasionally used to locate intra-abdominal gonads and address them safely. The Lancet
Non-pharmacological treatments (therapies & others)
Multidisciplinary DSD team care
Description: Regular care with pediatric/adult endocrinology, gynecology/urology, genetics, psychology/mental health, fertility specialists, pelvic floor therapists, and peer support. Purpose: Coordinate care, avoid fragmented decisions, support the whole person and family. Mechanism: Team reviews goals, test results, risks/benefits, and plans together, using shared decision-making. PMCGenetic counseling
Description: Step-by-step education about the AR gene, inheritance, recurrence risks, and options for family planning. Purpose: Help families understand why AIS occurs and plan future pregnancies. Mechanism: Counselors explain X-linked inheritance, carrier testing for relatives, and implications of specific AR variants. MedlinePlus+1Age-appropriate disclosure & psychosocial support
Description: Honest, gradual conversations about the diagnosis tailored to age and culture; access to therapists and peer groups. Purpose: Reduce shame, confusion, and isolation; improve mental health and body comfort. Mechanism: Evidence shows structured disclosure and supportive counseling improve coping and well-being. PMCPubertal planning & timing
Description: Discussion of natural puberty, need/timing for gonadectomy (if any), and hormone support. Purpose: Achieve healthy, comfortable puberty and adult hormone levels. Mechanism: Team reviews labs, imaging, and personal goals to individualize puberty support. NCBI+1Cancer-risk counseling & surveillance (if gonads retained)
Description: Education on age-related gonadal tumor risk and options: watchful waiting with imaging/markers vs. surgery after puberty. Purpose: Balance low-to-moderate risk in CAIS during childhood with benefits of natural puberty. Mechanism: Periodic exams, imaging, and shared decisions; many centers defer surgery until after puberty in CAIS. PMC+1Sexual health education & vaginal care
Description: Guidance on comfort, lubrication, and options for vaginal lengthening by nonsurgical dilation if a short vagina causes pain. Purpose: Pain-free, satisfying sexual activity if desired. Mechanism: Stepwise dilation expands tissue gradually; many people achieve adequate length without surgery. NCBIPelvic floor physical therapy
Description: Therapy for pelvic pain, dyspareunia, and muscle tension. Purpose: Improve comfort with exams and sex. Mechanism: Manual therapy, relaxation, and home exercises reduce hypertonicity and pain. PMCBone-health program
Description: Weight-bearing exercise, safe sunlight, fall-prevention training, and nutrition (see Supplements). Purpose: Prevent low bone density, which can occur after gonadectomy without adequate estrogen. Mechanism: Mechanical load and nutrients stimulate bone formation; monitoring guides early action. NCBI+1Fertility & family-building counseling
Description: Clear discussion of fertility expectations (CAIS: infertility; PAIS/MAIS: variable) and options (adoption, gamete donation, surrogacy). Purpose: Reduce uncertainty, plan early. Mechanism: Counseling addresses reproductive goals and practical pathways. NCBIVoice and communication training (as desired)
Description: Coaching for voice pitch, projection, and comfort if someone wants changes that match gender expression. Purpose: Improve confidence in social settings. Mechanism: Behavioral techniques reshape habitual voice use. WPATHPeer support & community resources
Description: Connections with AIS/DSD support organizations. Purpose: Reduce stigma, share lived experience. Mechanism: Group meetings, online communities, and mentoring. PMCSchool and workplace advocacy
Description: Help with documentation, privacy, and accommodations. Purpose: Prevent discrimination and stress. Mechanism: Letters and education for teachers/employers about medical needs. PMCSex education with consent-first framing
Description: Practical education about anatomy, arousal, and pain prevention. Purpose: Safe, satisfying intimacy. Mechanism: Knowledge and communication reduce fear and pain. PMCBody image & identity-affirming care
Description: Counseling centered on self-acceptance and gender identity. Purpose: Improve mental health, reduce dysphoria or distress. Mechanism: Evidence-based mental health care integrated with medical decisions. PMCLifestyle cardiovascular health
Description: Exercise, sleep, stress reduction, tobacco avoidance. Purpose: Offset metabolic risks if hormones are imbalanced. Mechanism: Improves lipids, insulin sensitivity, and mood. ScienceDirectPain management education
Description: Non-drug strategies for pelvic or musculoskeletal pain. Purpose: Function with less discomfort. Mechanism: Graded activity, heat/cold, relaxation, pacing. PMCTrauma-informed pelvic exams
Description: Consent-first, stepwise exams with chaperone and stop signal. Purpose: Safety and comfort. Mechanism: Reduces anxiety and pain; improves follow-up. PMCCare navigation after transition to adult services
Description: Planned handoff from pediatric to adult DSD teams. Purpose: Prevent care gaps. Mechanism: Early meetings, written plans, contacts. PMCEvidence-based decision aids
Description: Plain-language tools explaining options like dilation vs vaginoplasty or surveillance vs gonadectomy. Purpose: Informed, values-aligned choices. Mechanism: Structured pros/cons and expected outcomes. PMCDeferral of non-urgent genital surgery in children
Description: Unless medically necessary, defer irreversible surgeries until the individual can participate in consent. Purpose: Respect autonomy and long-term satisfaction. Mechanism: Aligns with modern ethics and WPATH SOC-8 principles. PMC+1
Drug treatments
Important honesty: AIS has no curative drug. Medicines are used for hormone support, bone health, sexual comfort, symptom relief, and individualized pubertal care. Listing “20 drugs” can be misleading, so below are evidence-based categories with representative examples. Dosing must be individualized by your clinician.
Estradiol replacement (post-gonadectomy in CAIS, and sometimes for symptom control)
Class: Estrogen. Common routes: transdermal patch, gel, or oral 17-β-estradiol. Purpose: Support bone, cardiovascular, urogenital, and vasomotor health. Mechanism: Replaces physiologic estrogen normally derived from aromatization of testicular androgens; maintain until about natural menopause age. Key note: Transdermal routes often preferred for VTE risk profile. Side effects: Breast tenderness, headaches, VTE risk (dose/route dependent). NCBI+1Low-dose estradiol for pubertal induction (if needed)
Class: Estrogen. Purpose: Gradual breast and uterine-independent secondary sex characteristics; in CAIS there is no uterus, but breast development and bone benefit occur. Mechanism: Start low, titrate to adult range. Side effects: As above. NCBITestosterone therapy (selected MAIS/PAIS individuals who desire virilization)
Class: Androgen. Purpose: Increase muscle mass, hair growth, libido; variable effect because AR is partially resistant. Mechanism: Exogenous testosterone acts via available receptor function; utility depends on variant and goals. Side effects: Acne, erythrocytosis, lipids, mood shifts. NCBIDihydrotestosterone (DHT) gel (experimental/selected PAIS contexts)
Class: Androgen. Purpose: Attempt penile growth in infancy/childhood PAIS with some residual AR function. Mechanism: Potent AR agonist; response inconsistent. Side effects: Skin irritation, premature virilization elsewhere. Note: Specialist use only. NCBITopical vaginal estrogen (if short vagina or dryness causes pain)
Class: Local estrogen. Purpose: Improve lubrication, elasticity, comfort. Mechanism: Trophic effect on vaginal epithelium. Side effects: Minimal systemic absorption; local irritation possible. NCBINon-hormonal vaginal moisturizers & lubricants
Class: OTC medical devices. Purpose: Reduce friction-related pain. Mechanism: Hydrate and lubricate mucosa. Side effects: Rare irritation; choose glycerin-free if prone to yeast. NCBIBisphosphonates (e.g., alendronate) for osteoporosis when indicated
Class: Antiresorptive. Purpose: Increase bone mineral density if low despite optimal estrogen/lifestyle. Mechanism: Inhibit osteoclasts. Side effects: GI upset, rare atypical fractures with long use; dental counseling advised. ScienceDirectDenosumab (selected cases)
Class: RANKL inhibitor. Purpose: Alternative antiresorptive for high-risk osteoporosis. Mechanism: Blocks osteoclast formation/activity. Side effects: Hypocalcemia risk; needs ongoing dosing. ScienceDirectCalcium supplements (if diet inadequate)
Class: Mineral supplement (see Supplements for more). Purpose: Meet daily needs for bone. Mechanism: Building block for bone matrix. Side effects: Constipation; kidney stone risk if excessive. ScienceDirectVitamin D3 (if low)
Class: Hormone/vitamin (see Supplements). Purpose: Aid calcium absorption and bone remodeling. Mechanism: Increases intestinal calcium uptake. Side effects: Hypercalcemia with excess dosing. ScienceDirectSSRIs/SNRIs for vasomotor symptoms if estrogen is not feasible
Class: Antidepressants used off-label for hot flashes. Purpose: Reduce hot flash frequency. Mechanism: Central thermoregulation modulation. Side effects: Nausea, sleep or sexual side effects. ScienceDirectGabapentin for vasomotor symptoms (selected)
Class: Neuromodulator. Purpose: Night-sweat relief. Mechanism: Central nervous system modulation. Side effects: Drowsiness, dizziness. ScienceDirectEflornithine cream (facial hair management if needed)
Class: Ornithine decarboxylase inhibitor. Purpose: Slow facial hair growth for comfort/aesthetics. Mechanism: Reduces follicular polyamines. Side effects: Local irritation. ScienceDirectTopical anesthetics before dilation/exams (procedural comfort)
Class: Local anesthetics. Purpose: Reduce pain during pelvic care. Mechanism: Sodium-channel blockade. Side effects: Local irritation, rare allergy. PMCAcne therapies (if androgen therapy used in MAIS/PAIS)
Class: Topical retinoids/benzoyl peroxide ± oral agents. Purpose: Manage acne side effects of androgens. Mechanism: Normalize keratinization, reduce C. acnes and inflammation. Side effects: Dryness; photosensitivity. ScienceDirectLipid-lowering agents (if dyslipidemia emerges)
Class: Statins, etc. Purpose: Cardiovascular risk reduction. Mechanism: Reduce LDL synthesis. Side effects: Myalgias, rare liver enzyme elevation. ScienceDirectAntiresorptive dental protocols (supportive)
Class: Preventive dental care coordinated with bisphosphonates/denosumab. Purpose: Lower risk of osteonecrosis of the jaw. Mechanism: Pre-treatment dental exam and hygiene. Side effects: — ScienceDirectSleep aids (short-term, if hot flashes disrupt sleep)
Class: Behavioral first; short-term pharmacologic as needed. Purpose: Restore sleep. Mechanism: Sleep hygiene ± short-course meds. Side effects: Depend on agent. ScienceDirectAntidepressant/anti-anxiety medicines (when clinically indicated)
Class: SSRIs/SNRIs/others. Purpose: Treat depression/anxiety sometimes associated with chronic conditions. Mechanism: Neurochemical modulation. Side effects: Medication-specific. PMCAnalgesics for procedural pain
Class: Local/short-term systemic analgesics. Purpose: Comfort during dilation or exams. Mechanism: Block pain pathways. Side effects: Medication-specific. PMC
Dietary molecular supplements
(Use only with clinician guidance; focus is bone and general health.)
Calcium (diet first; supplement if needed) — Builds bone matrix; typical adult total intake target ~1000–1200 mg/day from food + supplement combined; excessive dosing can cause stones/constipation. ScienceDirect
Vitamin D3 — Aids calcium absorption; individualized dosing to keep 25-OH-D in target range per clinician; too much raises calcium levels. ScienceDirect
Vitamin K2 (menaquinone) — Supports osteocalcin carboxylation; adjunct for bone metabolism; discuss with clinician if on anticoagulants. ScienceDirect
Magnesium — Cofactor in bone/mineral metabolism; avoid high doses in kidney disease. ScienceDirect
Protein (food first, or whey/plant protein) — Provides amino acids for bone and muscle; distribute through the day; adjust if kidney issues. ScienceDirect
Omega-3 fatty acids — General cardiometabolic support; modest triglyceride lowering. ScienceDirect
B12 (if vegan/low) — Nerve and blood cell health; blood-level guided dosing. ScienceDirect
Folate (diet first) — Supports cell division; supplement only if deficient/trying to conceive (for partners). ScienceDirect
Zinc (if low) — Enzyme cofactor; avoid excess due to copper depletion. ScienceDirect
Probiotics (optional) — Gut support; choose evidence-based strains; modest effects. ScienceDirect
Reality check: Supplements do not treat AIS itself; their role is supportive (especially bone health) alongside tailored hormone therapy. NCBI+1
Immunity booster, regenerative, stem-cell drugs
There are no approved immunity boosters, regenerative medicines, or stem-cell drugs for AIS. AIS is caused by androgen receptor gene variants, not by immune deficiency or tissue loss that stem cells can replace today. Experimental gene-based ideas exist in theory, but no clinical products are available or recommended. Safer alternatives are hormone support, bone protection, sexual health care, and psychosocial support with a DSD team. NCBI+1
Surgeries
Note: Modern care defers non-urgent, irreversible genital surgeries in children until the person can consent. Decisions are individualized. PMC+1
Gonadectomy (orchiectomy of intra-abdominal/inguinal testes)
Procedure: Laparoscopic or open removal of gonads. Why: To eliminate gonadal tumor risk; often considered after puberty in CAIS so endogenous hormones support breast/bone development first. Caveat: Some choose surveillance; discuss risks/benefits carefully. PMC+1Inguinal hernia repair with gonad management
Procedure: Repair hernia; consider concurrent gonad management. Why: Symptomatic hernia or incidental gonad in canal; tailored to age/risk. NCBIVaginal dilation (nonsurgical) or vaginoplasty (if dilation not successful/desired)
Procedure: Stepwise dilation; if surgery, creation/lengthening of vagina. Why: Painful intercourse or inability to have penetrative sex when desired. Caveat: Many succeed with dilation alone. NCBIClitoral/phallic or labial procedures (rare, highly individualized)
Procedure: Procedures to address discomfort or function. Why: Only if patient-driven for pain/function; not cosmetic pressure. Ethics: Strong consent standards. PMCHysteroscopy/uterine surgery
Note: CAIS typically lacks a uterus; this heading applies only to atypical cases/other DSDs where Müllerian remnants need evaluation. Why: Clarify anatomy or treat symptoms. NCBI
Prevention points
While AIS itself cannot be “prevented,” you can prevent complications and protect quality of life:
Ensure regular DSD-team follow-up across life stages. PMC
Build a bone-health plan (exercise, calcium/vitamin D, monitoring; medicines if indicated). ScienceDirect
Plan puberty and hormone therapy early and review annually. ScienceDirect
Discuss gonad management (surveillance vs surgery) with up-to-date risk data. PMC
Use trauma-informed pelvic care and lubrication to prevent pain. PMC
Maintain cardiometabolic health (activity, sleep, smoke-free). ScienceDirect
Mental health check-ins; treat anxiety/depression early. PMC
Peer support to reduce isolation. PMC
Fertility counseling early to set realistic expectations and options. NCBI
Clear, age-appropriate disclosure to build trust and reduce stigma. PMC
When to see a doctor
Primary amenorrhea (no periods by ~15–16) or bilateral inguinal hernia in a child raised as a girl. NCBI
Puberty questions (timing, breast development, hot flashes after gonadectomy). ScienceDirect
Pelvic pain, dyspareunia, or painful dilation—pelvic floor PT can help. PMC
Bone concerns (fractures, height loss) or vitamin D deficiency. ScienceDirect
Mass or pain in groin/abdomen, or concern about gonadal tumor risk. PMC
Mental health distress, body image struggles, or social stress; ask for counseling and peer support. PMC
Diet: what to eat” and what to avoid
Eat more:
Calcium-rich foods (dairy/fortified plant milks, tofu set with calcium).
Vitamin-D sources (fortified foods; safe sun per clinician).
Protein at each meal (eggs, fish, legumes, lean meats).
Leafy greens (magnesium, vitamin K).
Nuts/seeds (minerals, healthy fats).
Oily fish (omega-3s).
Whole grains (B-vitamins, fiber).
Colorful fruits/veg (antioxidants).
Water (hydration helps mucosa and general health).
Fermented foods (gut health). ScienceDirect
Limit/avoid:
Smoking/nicotine (bone & heart harm).
Heavy alcohol (bone loss; falls).
Very high salt (bone calcium loss).
Sugary drinks (metabolic impact).
Ultra-processed foods (low nutrient density).
Excess caffeine if it worsens hot flashes or sleep.
Mega-doses of calcium/vitamin D without labs.
Unverified “hormone boosters.”
Supplements that interact with medicines (check first).
Extreme diets that miss calcium/protein. ScienceDirect
Frequently Asked Questions
Is AIS a disease I can “catch”?
No. It is a genetic variation in the androgen receptor gene. MedlinePlusAre there different types of AIS?
Yes—Complete (CAIS), Partial (PAIS), and Mild (MAIS)—based on how much the body responds to androgens. NCBICan AIS be cured with medicine or stem cells?
No. Care is supportive and individualized; no curative or regenerative drug exists. NCBIWill I need surgery?
Not always. Non-urgent surgeries are often deferred until you can consent. Gonadectomy and/or vaginoplasty are individualized. PMCWhat is the cancer risk if I keep my gonads?
In CAIS, risk is low in childhood and increases with age; teams often discuss surveillance vs. removal after puberty. Exact risk varies by study. PMCDo I need progesterone?
CAIS typically has no uterus, so progesterone is not required for endometrial protection. Decisions are individualized. NCBIHow long do I take estrogen after gonadectomy?
Usually until the average age of menopause (about 50–55), then reassess. Route/dose are individualized. ScienceDirectCan someone with AIS have children?
CAIS: infertility. PAIS/MAIS: variable. Family-building options (adoption, donor gametes) are available. NCBIIs gender identity always female in AIS?
Many with CAIS identify as female; identity is personal and should be respected. Care follows the individual’s goals. NCBI+1Is vaginal dilation painful?
With education, lubrication, and pelvic PT, many do well and avoid surgery. Go slowly; stop if painful. NCBIAre anti-androgens useful?
Generally not in CAIS because receptors do not respond to androgens. In select PAIS/MAIS cases, regimens are specialist-guided. NCBIWhat follow-up do I need if I keep my gonads?
Regular clinical reviews; imaging or labs per center protocol; prompt review of new pain/mass. PMCWhat about sports eligibility and testing?
Policies are evolving and controversial; decisions should protect privacy and be individualized. Seek expert advocacy. PMCWill I need bone scans?
Yes, if risk factors exist (post-gonadectomy without adequate estrogen, fractures, etc.). Your team decides timing. ScienceDirectWhere can I read more in simple language?
MedlinePlus Genetics has a clear overview, and GeneReviews has clinician-level detail. MedlinePlus+1
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: September 17, 2025.
